Kiromic BioPharma (NASDAQ:KRBP) stock is rocketing higher on Tuesday after the company announced a new sponsored research agreement.
This agreement has Kiromic teaming up with Principal Investigator James Welsh, M.D. of The University of Texas MD Anderson Cancer Center. The SRA will see the company producing preclinical data from its GDT allogeneic therapies.
More About Kiromic BioPharma Stock
The post Why Is Kiromic BioPharma (KRBP) Stock Up 75% Today? originally appeared at InvestorPlace.